Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075647 · ClinicalTrials.gov registry record · Phase 2
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00075647 is a Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 77-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00075647, a Phase 2 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with locally advanced or metastatic pancreatic cancer
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG temsirolimus
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075647
The ClinicalTrials.gov registry entry for NCT00075647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (48% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00075647 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00075647 about?
NCT00075647 is a clinical study titled "CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer". Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with locally advanced or metastatic pancreatic cancer
What is the current status of trial NCT00075647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2003-12.
What conditions does trial NCT00075647 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer.
What interventions are being tested in trial NCT00075647?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00075647?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00075647 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.